The Medicines Company (Nasdaq: MDCO) has announced positive top-line results for the ORION-9 and ORION-10 Phase III studies of inclisiran.
The New Jersey, USA-based firm is testing the candidate against heterozygous familial hypercholesterolemia (HeFH), an autosomal dominant disorder which causes cholesterol levels to become highly elevated.
The studies met all primary and secondary endpoints, showing durable and potent efficacy. The therapy was well-tolerated with a good safety profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze